pyrazines has been researched along with tanespimycin in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (45.45) | 29.6817 |
| 2010's | 12 (54.55) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, J; Elliott, PJ | 1 |
| Bonvini, P; Dalla Rosa, H; Rosolen, A; Vignes, N | 1 |
| Bisht, KS; Gius, D; Isaacs, JS; Mimnaugh, EG; Neckers, L; Vos, M; Xu, W; Yuan, X | 1 |
| Akiyama, M; Anderson, KC; Bailey, C; Chauhan, D; Davies, FE; Gu, X; Hideshima, T; Joseph, M; Kung, AL; Libermann, TA; McMullan, CJ; Mitsiades, CS; Mitsiades, NS; Morgan, G; Munshi, NC; Poulaki, V; Richardson, PG; Rosen, NS; Shringarpure, R | 1 |
| Anderson, KC; Hideshima, T; Ikeda, H; Ishitsuka, K; Jin, J; Kiziltepe, T; Moss, N; Ocio, EM; Okawa, Y; Pargellis, C; Podar, K; Raje, N; Richardson, PG; Vallet, S; Yasui, H | 1 |
| Walker, K | 1 |
| Strobeck, M | 1 |
| Andreeff, M; Ashihara, E; Kamitsuji, Y; Kawata, E; Kimura, S; Kuroda, J; Maekawa, T; O'Reilly, LA; Strasser, A; Tabe, Y; Takeuchi, M; Tanaka, R; Taniwaki, M; Yokota, A | 1 |
| Clarke, PA; Powers, MV; Workman, P | 1 |
| Cippitelli, M; Fionda, C; Iannitto, ML; Malgarini, G; Santoni, A; Soriani, A | 1 |
| Albitar, M; Anderson, KC; Badros, AZ; Berman, D; Jagannath, S; Messina, M; Richardson, PG; Tarantolo, S; Wolf, JL | 1 |
| Chosa, M; Nagase, K; Tobinai, K; Watanabe, T | 1 |
| Campo, E; Colomer, D; López-Guerra, M; Mozos, A; Normant, E; Pérez-Galán, P; Rosich, L; Roué, G; Saborit-Villarroya, I; Xargay-Torrent, S | 1 |
| Albitar, M; Alsina, M; Anderson, KC; Berman, D; Carroll, MP; Chanan-Khan, AA; Krishnan, AY; Lonial, S; Messina, M; Richardson, PG | 1 |
| Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
| Anderson, KC; Blumenthal, M; Cirstea, D; Fabre, C; French, M; Fulciniti, M; Gorgun, G; Hokenson, M; Hu, Y; Ikeda, H; Kawano, Y; Kertesz, NL; Kiziltepe, T; Malyankar, UM; Mimura, N; Minami, J; Munshi, NC; Ohguchi, H; Patterson, JB; Pham, T; Richardson, PG; Santo, L; Tai, YT; Tam, V; Zeng, Q | 1 |
| Binkley, P; Blum, KA; Blum, W; Byrd, JC; Garzon, R; Geyer, S; Grever, MR; Jiang, Y; Johnston, JS; Kefauver, C; Klisovic, R; Marcucci, G; Phelps, MA; Walker, AR | 1 |
| Ames, MM; Erlichman, C; Hendrickson, AE; Menefee, M; Northfelt, D; Qin, R; Satele, D; Schenk, E; Toft, DO | 1 |
| Bodeen, WJ; Han, YG; Marada, S; Ogden, SK; Stewart, DP | 1 |
| Fischer, U; Hoffmann, MJ; Jung, M; Niegisch, G; Rosik, L; Schulz, WA | 1 |
| Dakhil, C; Haideri, N; Kumar, AK; Teeka Satyan, M | 1 |
| Chen, A; Hao, M; Jin, H; Lian, N; Shao, J; Wu, L; Yao, Z; Zhang, F; Zheng, S | 1 |
2 review(s) available for pyrazines and tanespimycin
| Article | Year |
|---|---|
New agents in cancer clinical trials.
Topics: Antineoplastic Agents; Benzamides; Benzoquinones; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dioxoles; Enzyme Inhibitors; Humans; Hydroxamic Acids; Imatinib Mesylate; Isoquinolines; Lactams, Macrocyclic; Neoplasms; Piperazines; Pyrazines; Pyrimidines; Rifabutin; Stilbenes; Tetrahydrofolates; Tetrahydroisoquinolines; Trabectedin; Vorinostat | 2000 |
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
4 trial(s) available for pyrazines and tanespimycin
| Article | Year |
|---|---|
Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; HSP70 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Leukocyte Count; Male; Middle Aged; Multiple Myeloma; Neutrophils; Platelet Count; Pyrazines; Recurrence; Treatment Outcome | 2010 |
Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Humans; Lactams, Macrocyclic; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Treatment Outcome | 2011 |
Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Boronic Acids; Bortezomib; Electrocardiography; Female; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Leukemia, Myeloid, Acute; Male; Middle Aged; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Pyrazines; Recurrence; Torsades de Pointes; Treatment Outcome | 2013 |
Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Humans; Lactams, Macrocyclic; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyrazines; Treatment Outcome | 2013 |
16 other study(ies) available for pyrazines and tanespimycin
| Article | Year |
|---|---|
Ubiquitination and proteasomal degradation of nucleophosmin-anaplastic lymphoma kinase induced by 17-allylamino-demethoxygeldanamycin: role of the co-chaperone carboxyl heat shock protein 70-interacting protein.
Topics: Animals; Apoptosis; Benzoquinones; Boronic Acids; Bortezomib; Cell Fractionation; Chlorocebus aethiops; COS Cells; Cysteine Endopeptidases; Detergents; Down-Regulation; Humans; Lactams, Macrocyclic; Multienzyme Complexes; Protease Inhibitors; Proteasome Endopeptidase Complex; Protein-Tyrosine Kinases; Pyrazines; Rifabutin; Transfection; Ubiquitin; Ubiquitin-Protein Ligases | 2004 |
Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity.
Topics: Antineoplastic Agents; Benzoquinones; Boronic Acids; Bortezomib; Cell Line, Transformed; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell Transformation, Viral; Cycloheximide; Detergents; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Oncogene Proteins, Viral; Papillomavirus E7 Proteins; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteins; Pyrazines; Quinones; Repressor Proteins; Rifabutin; Solubility; Ubiquitins; Vacuoles | 2004 |
Antimyeloma activity of heat shock protein-90 inhibition.
Topics: Androgens; Antineoplastic Agents; Apoptosis; Benzoquinones; Boronic Acids; Bortezomib; Drug Synergism; Estrogens; Fusion Proteins, bcr-abl; HSP90 Heat-Shock Proteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; I-kappa B Kinase; Lactams, Macrocyclic; Multiple Myeloma; Proto-Oncogene Proteins c-akt; Pyrazines; raf Kinases; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Interleukin-6; Rifabutin; Signal Transduction; Tumor Cells, Cultured | 2006 |
BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Benzoquinones; Boronic Acids; Bortezomib; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Cytotoxicity Tests, Immunologic; Dexamethasone; Drug Resistance, Neoplasm; HSP90 Heat-Shock Proteins; Humans; Immunoblotting; Interleukin-6; Intracellular Signaling Peptides and Proteins; Lactams, Macrocyclic; Multiple Myeloma; Naphthalenes; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Pyrazoles; Signal Transduction; Stem Cells; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2007 |
American Society of Hematology--48th Annual Meeting and Exposition. Updates on hematological therapies. 9-12 December 2006 Orlando, FL, USA.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Boronic Acids; Bortezomib; Hematologic Neoplasms; Hematology; Humans; Indoles; Janus Kinase 2; Lactams, Macrocyclic; Myeloproliferative Disorders; Phosphorylcholine; Pyrazines | 2007 |
Multiple myeloma therapies.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Boronic Acids; Bortezomib; Clinical Trials as Topic; HSP90 Heat-Shock Proteins; Humans; Immunosuppressive Agents; Lactams, Macrocyclic; Melphalan; Multiple Myeloma; Pyrazines; Thalidomide | 2007 |
Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Benzoquinones; Biphenyl Compounds; Boronic Acids; Bortezomib; Cell Line, Transformed; Cell Line, Tumor; Humans; Imatinib Mesylate; Lactams, Macrocyclic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-bcr; Pyrazines; Pyrimidines; Sulfonamides | 2007 |
Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis.
Topics: Apoptosis; Benzoquinones; Boronic Acids; Bortezomib; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 4; HCT116 Cells; HSC70 Heat-Shock Proteins; HSP70 Heat-Shock Proteins; HSP72 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Kinetics; Lactams, Macrocyclic; Neoplasms; Poly(ADP-ribose) Polymerases; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Isoforms; Proto-Oncogene Proteins c-raf; Pyrazines; RNA, Small Interfering; Transfection; Ubiquitination | 2008 |
Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation.
Topics: Benzoquinones; Boronic Acids; Bortezomib; Cell Degranulation; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Histocompatibility Antigens Class I; HSP90 Heat-Shock Proteins; Humans; Intercellular Signaling Peptides and Proteins; Killer Cells, Natural; Lactams, Macrocyclic; Ligands; Multiple Myeloma; Protein Folding; Pyrazines; Up-Regulation | 2009 |
Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathy.
Topics: Animals; Antineoplastic Agents; Autophagy; Benzoquinones; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Clonazepam; HSP90 Heat-Shock Proteins; Lactams, Macrocyclic; Multiple Myeloma; Neurilemmoma; Protein Folding; Proteostasis Deficiencies; Pyrazines; Rats; Schwann Cells | 2010 |
The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Benzoquinones; Boronic Acids; Bortezomib; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lymphoma, Mantle-Cell; Male; Mice; Mice, SCID; Mice, Transgenic; Middle Aged; Molecular Chaperones; Pyrazines; Receptors, Estrogen; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; eIF-2 Kinase; Endoplasmic Reticulum Stress; Endoribonucleases; Enzyme Activation; Enzyme Inhibitors; Humans; Interleukin-6; Lactams, Macrocyclic; Mice; Multiple Myeloma; Protein Serine-Threonine Kinases; Pyrazines; Regulatory Factor X Transcription Factors; RNA Splicing; RNA, Messenger; Signal Transduction; Stromal Cells; Transcription Factors; Unfolded Protein Response; X-Box Binding Protein 1 | 2012 |
The unfolded protein response selectively targets active smoothened mutants.
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Benzoquinones; Boronic Acids; Bortezomib; Carcinoma, Basal Cell; Cell Line; DNA-Binding Proteins; Drosophila melanogaster; Drosophila Proteins; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; Enzyme Inhibitors; Green Fluorescent Proteins; Hedgehog Proteins; Heterocyclic Compounds, 4 or More Rings; HSP90 Heat-Shock Proteins; Lactams, Macrocyclic; Medulloblastoma; Mice; Mutant Proteins; Pyrazines; Receptors, G-Protein-Coupled; RNA Interference; RNA, Small Interfering; Signal Transduction; Smoothened Receptor; Thapsigargin; Ubiquitin-Protein Ligases; Unfolded Protein Response | 2013 |
Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells.
Topics: Acetylation; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Benzoquinones; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Gene Expression; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Indoles; Inhibitory Concentration 50; Lactams, Macrocyclic; Middle Aged; Protein Processing, Post-Translational; Pyrazines; Urinary Bladder Neoplasms; Urothelium | 2014 |
Extramedullary progression of multiple myeloma despite concomitant medullary response to multiple combination therapies and autologous transplant: a case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Biopsy; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Diagnosis, Differential; Disease Progression; Doxorubicin; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Lactams, Macrocyclic; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Transplantation, Autologous | 2014 |
Canonical hedgehog signalling regulates hepatic stellate cell-mediated angiogenesis in liver fibrosis.
Topics: Animals; Benzoquinones; Carbon Tetrachloride; Disease Models, Animal; Hedgehog Proteins; Hepatic Stellate Cells; HSP90 Heat-Shock Proteins; Hypoxia-Inducible Factor 1, alpha Subunit; Lactams, Macrocyclic; Liver Cirrhosis; Male; Mice; Mice, Inbred ICR; Mustard Compounds; Neovascularization, Pathologic; Phenylpropionates; Pyrazines; Rats; Rats, Sprague-Dawley; Signal Transduction; Smoothened Receptor | 2017 |